Overview
Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.
Background
Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.
Indication
Used in the induction of general anesthesia.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/10 | Early Phase 1 | Not yet recruiting | Second Hospital of Shanxi Medical University | ||
2025/03/05 | Phase 3 | Not yet recruiting | Ahon Pharmaceutical Co., Ltd. | ||
2024/11/12 | Phase 2 | Completed | Ahon Pharmaceutical Co., Ltd. | ||
2024/10/29 | Phase 4 | Completed | Yeongseok Yun | ||
2024/01/12 | Phase 3 | Recruiting | Ahon Pharmaceutical Co., Ltd. | ||
2023/12/22 | N/A | ENROLLING_BY_INVITATION | |||
2023/10/05 | Phase 4 | Recruiting | |||
2023/04/12 | Not Applicable | Completed | Ailin Luo | ||
2023/03/01 | Not Applicable | Completed | Xijing Hospital | ||
2022/08/30 | Not Applicable | UNKNOWN |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Eugia US LLC | 55150-221 | INTRAVENOUS | 20 mg in 10 mL | 7/5/2023 | |
| Armas Pharmaceuticals Inc. | 72485-509 | INTRAVENOUS | 2 mg in 1 mL | 1/22/2024 | |
| Fresenius Kabi USA, LLC | 65219-447 | INTRAVENOUS | 2 mg in 1 mL | 7/14/2021 | |
| Zydus Pharmaceuticals USA Inc. | 68382-545 | INTRAVENOUS | 2 mg in 1 mL | 11/14/2022 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1459 | INTRAVENOUS | 2 mg in 1 mL | 10/10/2023 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1455 | INTRAVENOUS | 2 mg in 1 mL | 2/23/2020 | |
| Caplin Steriles Limited | 65145-128 | INTRAVENOUS | 2 mg in 1 mL | 12/30/2020 | |
| Hikma Pharmaceuticals USA Inc. | 0143-9507 | INTRAVENOUS | 2 mg in 1 mL | 12/6/2023 | |
| Hikma Pharmaceuticals USA Inc. | 0143-9506 | INTRAVENOUS | 2 mg in 1 mL | 12/6/2023 | |
| Eugia US LLC | 55150-222 | INTRAVENOUS | 40 mg in 20 mL | 7/5/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| ETOMIDATE-LIPURO INJECTION 20 mg/10 ml | SIN08849P | INJECTION | 20 mg/10 ml | 8/14/1996 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Etomidate Injection | 国药准字H32022992 | 化学药品 | 注射剂 | 7/14/2020 | |
| Etomidate Injection | 国药准字H32022379 | 化学药品 | 注射剂 | 8/31/2020 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字H20249049 | 化学药品 | 注射剂 | 10/16/2024 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字H20254019 | 化学药品 | 注射剂 | 4/30/2025 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字H20244346 | 化学药品 | 注射剂 | 6/28/2024 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字H20234161 | 化学药品 | 注射剂 | 9/12/2023 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字H20249700 | 化学药品 | 注射剂 | 12/6/2024 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字H20249756 | 化学药品 | 注射剂 | 12/17/2024 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字HJ20160234 | 化学药品 | 注射剂 | 3/15/2021 | |
| Etomidate Medium and Long Chain Fat Emulsion Injection | 国药准字H20233206 | 化学药品 | 注射剂 | 2/21/2023 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| ETOMIDATE-LIPURO INJ 20MG/10ML | N/A | b. braun medical (hk) ltd | N/A | N/A | 1/10/1996 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||